Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.

Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m(2)) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2-14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.
AuthorsMasashi Takano, Yoshihiro Kikuchi, Kazuya Kudoh, Tomoko Goto, Kenichi Furuya, Ryoko Kikuchi, Tsunekazu Kita, Keiichi Fujiwara, Tanri Shiozawa, Daisuke Aoki
JournalInternational journal of clinical oncology (Int J Clin Oncol) Vol. 16 Issue 5 Pg. 605-9 (Oct 2011) ISSN: 1437-7772 [Electronic] Japan
PMID21243393 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • CA-125 Antigen
  • temsirolimus
  • Sirolimus
  • Adenocarcinoma, Clear Cell (drug therapy, pathology)
  • Antineoplastic Agents (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols
  • CA-125 Antigen (blood)
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms (drug therapy, pathology)
  • Sirolimus (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: